Salarius Pharmaceuticals (SLRX) Competitors

Salarius Pharmaceuticals logo
$1.76 -0.05 (-2.49%)
As of 03:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SLRX vs. DWTX, TXMD, BCDA, PMCB, KPRX, TLPH, BCTX, PHXM, AEON, and CYCN

Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Dogwood Therapeutics (DWTX), TherapeuticsMD (TXMD), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), BriaCell Therapeutics (BCTX), PHAXIAM Therapeutics (PHXM), AEON Biopharma (AEON), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

Salarius Pharmaceuticals vs.

Salarius Pharmaceuticals (NASDAQ:SLRX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Salarius Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

In the previous week, Salarius Pharmaceuticals and Salarius Pharmaceuticals both had 3 articles in the media. Salarius Pharmaceuticals' average media sentiment score of 1.27 beat Dogwood Therapeutics' score of 0.63 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Salarius Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dogwood Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Salarius PharmaceuticalsN/AN/A-$12.54M-$8.17-0.21
Dogwood TherapeuticsN/AN/A-$5.30M-$6.55-1.14

11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 1.4% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Salarius Pharmaceuticals' return on equity of -140.28% beat Dogwood Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Salarius PharmaceuticalsN/A -140.28% -105.76%
Dogwood Therapeutics N/A -217.12%-172.06%

Salarius Pharmaceuticals received 26 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Salarius PharmaceuticalsOutperform Votes
26
54.17%
Underperform Votes
22
45.83%
Dogwood TherapeuticsN/AN/A

Summary

Salarius Pharmaceuticals beats Dogwood Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Salarius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLRX vs. The Competition

MetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.75M$6.89B$5.69B$9.02B
Dividend YieldN/A2.91%5.32%4.00%
P/E Ratio-0.219.2388.8019.29
Price / SalesN/A307.871,019.3675.13
Price / CashN/A75.4646.0938.87
Price / Book0.165.485.054.99
Net Income-$12.54M$123.50M$113.53M$222.83M
7 Day Performance-20.91%-4.89%-1.49%-0.86%
1 Month Performance11.18%-2.48%3.24%2.55%
1 Year Performance-61.19%1.49%20.85%17.62%

Salarius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRX
Salarius Pharmaceuticals
1.3418 of 5 stars
$1.77
-2.5%
N/A-60.2%$2.79MN/A-0.2220Short Interest ↓
Positive News
DWTX
Dogwood Therapeutics
N/A$8.77
-18.3%
N/AN/A$11.68MN/A-1.345
TXMD
TherapeuticsMD
1.2636 of 5 stars
$1.01
-1.0%
N/A-56.3%$11.65M$1.60M0.00420Short Interest ↓
Gap Down
BCDA
BioCardia
3.241 of 5 stars
$2.37
flat
$25.00
+954.9%
-59.5%$10.86M$480,000.00-0.5740Short Interest ↑
News Coverage
Gap Down
PMCB
PharmaCyte Biotech
1.4504 of 5 stars
$1.55
+4.0%
N/A-26.3%$10.80MN/A2.924Short Interest ↑
Positive News
Gap Down
KPRX
Kiora Pharmaceuticals
2.9863 of 5 stars
$3.60
flat
$10.00
+177.8%
-46.8%$10.80MN/A0.0010Short Interest ↑
News Coverage
TLPH
Talphera
3.3397 of 5 stars
$0.63
-3.1%
$4.33
+587.9%
-32.2%$10.73M$650,000.00-0.9119Positive News
BCTX
BriaCell Therapeutics
3.296 of 5 stars
$3.62
-2.9%
$32.00
+784.0%
-94.2%$10.68MN/A-0.278Short Interest ↓
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049
AEON
AEON Biopharma
2.8594 of 5 stars
$0.13
-0.3%
$5.00
+3,749.1%
-98.5%$10.39MN/A0.725Gap Down
CYCN
Cyclerion Therapeutics
1.3697 of 5 stars
$3.82
-9.3%
N/A-11.5%$10.35M$1.62M0.0030Short Interest ↑
Gap Down

Related Companies and Tools


This page (NASDAQ:SLRX) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners